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KAJIAN FARMAKOKINETIKDAN METABOLISME UBAT-UBATAN 
ANTIFILARIA TERBIT AN BENZIMIDAZOLA KARBAMAT 
ABSTRAK 
Farmakokinetik dan metabolisme dua jenis drug ani filaria baru UMF-078 dan UMF-058 
telah dikaji dalam model haiwan yang sesuai dengan perekaan bagi aspek penyerapan 
drug dan metabolisme. Kaedah-kaedah kromatografi cecair keupayaan tinggi yang 
spesifik dan sensitif bagi UMF-078, UMF-058 dan metabolitnya telah 
diperkembangkan. Kaedah-kaedah ini digunakan untuk mengkaji kesan formulasi, 
regimen dos dan cara pemberian drug ke atas penyerapan dalam model haiwan monyet 
dan anjing. Dalam monyet sihat, formulasi garam UMF-078 menunjukkan penyerapan 
yang lebih tinggi daripada bagi UMF-078 bes. Dalam kajian peningkatan dos, 
penyerapan drug sebanyak 3 112 kali ganda diperhatikan apabila dos ditngkatkan 
daripada 100 mg/kg ke 200 mg/kg. Penyerapan drug (AUC) melalui laluan otot 
didapati lebih kecil dan eratik dari laluan oral. Kesan formulasi dan regimen dos ke 
atas penyerapan drug UMF-078 juga dikaji bagi model anjing. Dalam anjing sihat, 
.. 
penyerapan drug UMF-078 bagi formulasi garam dan bes tidak berbeza. Penyerapan 
drug UMF-078 didapati bertarnbah apabila drug UMF-078 diberi sebagai pecahan dos 
·~~ ~ 
berbanding (150 mglkgx 2; 50 mglkg x b.i.d. x 3) dengan dos tunggal (300 mg/kg). 
Kajian keseluruhan dengan monyet dan anjing juga menunjukkan bahawa UMF-060 
dan flubendazola adalah metabolit minor. Farmakokinetik dan efikasi drug UMF-078 
dalarn monyet yang dijangkiti dengan cacing Brugia malayi juga dikaji. kedua-dua 
regimen dose tunggal dan berganda (50 mglkg x 5) menunjukkan penyerapan drug 
XV 
(AUCo-t) yang hampir sama. kedua-dua regimen dos tunggal dan berganda didapati tidak 
menunjukkan aktiviti antifilaria ke atas cacing dewasa. Walau bagaimanapun, regimen 
dose berganda menunjukkan aktiviti antifilaria ke atas microfilaria. 
Metabolisme drug UMF-078 juga dikaji dalam model haiwan tikus. UMF-078 dan 
metabolitnya UMF-060, FBZ mengalami hidrolisis karbamat. Kepentingan metabolit 
adalah dalam susunan berikut D-UMF-078 < D-UMF-060 < FBZ < UMF-060 < D-FBZ. 
Metabolisme drug UMF-078 dan FBZ juga dibandingkan dengan menggunakan model 
haiwan tikus. Dalam metabolisme drug UMF-078, metabolit seperti D-UMF-060, 
UMF-060 dan D-FBZ, di kesan dalam darah tikus yang diberi drug UMF-078. 
Sebaliknya produk-produk ini tidak dijumpai dalam tikus yang diberi drug FBZ. 
Perhatian ini mencadangkan bahawa, ada kemungkinan metabolit ini terbit daripada 
tapak jalan metabolisme UMF-078 yang lain dan bukannya daripada flubendazola. 
Kajian pra-klinikal ini keseluruhannya menambahkan lagi pengetahuan asas tentang 
drug UMF-078 yang boleh membantu dalam penyelidikan seterusnya . 
. .. 
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ABSTRACT 
The pharmacokinetics and metabolism of two new antifilarial drugs, UMF-078 and 
UMF-058 have been investigated in suitable animal models with special emphasis on 
drug absorption and drug metabolism, the latter was to determine the possible 
metabolic products follO\ving metabolism in rats. Specific and sensitive high 
performance liquid chromatography techniques (HPLC) for UMF-078, UMF-058 and 
their respective putative metabolites has been developed. The availability of these 
HPLC techniques further facilitated investigation of the effects of dose regimens, 
formulation and routes on drug absorption in monkeys and dogs. In healthy monkeys, 
UMF-078 absorption was relatively better for UMF-078 salt than of UMF-078 base. 
With respect to dose escalation study of UMF-078 base a 3 1/2 fold increment in UMF-
078 absorption (AUC) was encountered when the dose was doubled from 100 to 200 
mglkg. The effect of routes (i.m. vs. oral) on drug absorption in monkeys was also 
investigated Following i.m. administration UMF-078 absorption was observed to be 
poor and erratic when compared to oral administration of the same dosing schedule 
animals. 
. .. 
Studies were also initiated in dogs to investigate the effect of formulation and dose size 
on drug absorption. The overall absorption of UMF-078 is similar in group of animals 
receiving either UMF-078 salt or UMF-078 base .UMF-078 absorption was found to 
increase when the drug was given as divided dose (150 mglkg x 2; 50 mglkg x b.i.d. x 
3) as compared to those administered with a single bolus dose of 300 mglkg of UMF-
078. In addition studies in dogs and monkeys also tend to suggest that FBZ and UMF-
060 were not the major metabolites ofUMF-078. 
XVIl 
The pharmacokinetics and efficacy of UMF-058 in monkeys infected with Brugia 
malayi were also investigated. The overall UMF-058 oral absorption (AUCo-t) was 
similar for both single (250 mg/kg) and multiple dose regimen (50 mg/kg x 5). Neither 
single nor multiple oral dose regimens demonstrated adultcidal activity against B. 
malayi in infected monkeys. However, multiple dose regimen of UMF-058 was 
microfilaricidal against B. malayi. The metabolism of UMF-078 was investigated in 
rats. UMF-078 and its metabolites FBZ and UMF-060 all undergo carbamate hydrolysis. 
The importance ofthese metabolites were found in the order ofD-UMF-078 < D-UMF-
060 < FBZ < UMF-060 < D-FBZ. A comparative metabolism study of UMF-078 and 
FBZ in rats were also initiated. D-UMF-060, UMF-060 and D-FBZ were encountered in 
blood of rats having received UMF-078 but not in animals treated with FBZ. This tend 
to suggest that these metabolites probably derived from other alternative pathway of 
UMF-078 rather than via FBZ. The pre-clinical information described has improved our 
understanding of UMF-078 and thus provides the basis for further evaluation of this 
new candidate antifilarial compound 
... 
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CHAPTER 1 
INTRODUCTION· 
1.1 General Introduction 
Filariasis was probably known as early as 600 - 250 BC as people with 
elephantiasis were excluded from the Buddhist priesthood (Laurence, 1967). 
Microfilariae probably that of Wuchereria bancrofti origin was first noted in the 
hydrocoele fluid of a man who originated from Havana (Demarquay, 1863) 
subsequently in the urine of haematuric patients in Brazil (Wucherer, 1868) and in 
human blood in India (Lewis, 1872). Manson, (1899) also first observed the 
characteristic of nocturnal periodicity in microfilaria of W bancrofti and subsequently 
describe the localization of microfilaria in lungs and cardiac muscles during the day. 
Manson, ( 1878) demonstrated the occurrence of micro filariae in the blood of patients 
with elephantiasis and latter associated this and other clinical signs of lymphatic 
obstruction with the infection. Low (1900) on the basis of histological studies on 
infected mosquitos was the first to propose correctly that human are infected following 
a mosquito bite. Filariasis is a disease caused by nematodes belonging to the 
superfamily filariodea, family onchocercidae. Parasite known to cause human 
infections belong mainly to genera Wuchereria, Brugia, Onchocerca, Dipetalonema, 
~) .,..-:'-
Mansonella, Loa and Dirofilaria. (Manson et a!., 1982~ Ottesen, 1987). Only 
Wuchereria bancrofti, Brugia malayi and Brugia timori are known to cause human 
lymphatic filariasis. The adults of these three species normally live in the lymphatic 
system and thus are commonly said to produce lymphatic filariasis. W. bancrofti and 
B. malayi are mainly responsible for human filariasis in Malaysia and the surrounding 
countries. 
Filariasis is a morbid condition disease which leads to considerable socto 
economic effects. Clearly, people with gross elephantiasis are severely impaired both 
physically and socially and the prevalence of elephantiasis alone makes lymphatic 
filariasis an important public health problem. Lymphatic filariasis infection is most 
prominent in subtropical and tropical regions of the world. To date an estimated 78.9 
million are infected, as evidenced by microfilariae in blood samples and clinical 
symptoms. Of this figure, 72.8 million are infected by W bancrofii and 5.8 million 
with B. malayi or B. timori (Ramachandran, 1994). Ideally for any control programme 
to be effective, the community must be acquainted with not only the modem tools and 
techniques used but also an acceptable way of thinking about the causation of the 
disease and its treatment. A successful programme for the control of lymphatic 
filariasis is usually based on a thorough understanding of its distribution and the 
dynamics of the disease in the aimed populations. However, the diverse demographic 
environmental and socioeconomic characteristics of population in endemic areas of 
lymphatic filariasis as well as differences in vector, parasite and disease parameters, do 
... 
not allow a simple, uniform approach for control programmes to be implemented. 
Hence, each of the control strategies need to be tailored to the unique circumstances of 
-a particular affected PQpulatiori' and also its environment and ecology. Unfortunately, in 
most of the endemic areas ofthe world, there is at present no effective filariasis control. 
The main reasons are filariasis is not accepted as a public health priority by health 
officials and most control programmes are too complicated and costly to be sustained. 
Methods used to control this vector borne disease such as the use of insecticides have 
2 
~·· demonstrated vague results (Chiang et al., 1989). This being mainly due to the 
resistance developed by these mosquitos towards insecticides. Biological control which 
is an innovative method of controlling this vector borne disease is still in the early 
stages. For instance Bacillus sphericus a biological insecticide is currently effectively 
used agains Culex species for large scale control (Arunachalam et a/., 1991 ). Still more 
work need to be done to assess the possibility of using this method to disrupt the filarial 
vector in the remaining endemic areas. However, it might be more appropriate to 
emphasize on the development and implementation of simple, cost-effective and 
sustainable programmes for morbidity control. In view of this, chemotherapy plays a 
key role in controlling lymphatic filariasis. The situation has stimulated research into 
better and more effective usage of the currently available drugs and development of 
new antifilarial agents. 
1.2 The pathology and clinical manifestation of lymphatic filariasis. 
1.2.1 The filarial life cycle 
In order to develop control strategies for this disease it is essential to delineate the host, 
parasite and vector relationship by knowing the lifecycle of ftlariasis (Fig.l.l ). The life 
cycle of B. malayi and W bancrofti are essentially similar. The adult worms normally 
0 •• 
resides in the lymphatic systems of infected humans. Following mating, female worms 
release blood circulating microfilariae into surrounding tissue. The microfilaremic host 
then serves as the source of infection to vector mosquitoes which depending on the 
locality belong to either or a combination of the genera mansonia, anopheles, culex and 
aedes. Following mosquito bite, microfilariae is taken up to the thoracic muscles of the 
mosquito, where the parasite that undegoes development becomes thicker and shorter 
than its initial size. The first stage of larva (Ll) at 2.5 days has an average length of 
3 
143.7 ± 3.8 J.Lm and a maximum width of 16.5 ± 0.7J.lm. The development of L1 to 
second stage larva (L2) occurs at about day 5. The length and maximum width of this 
L2 at day 5.5 are 441 ± 27 J.Lm and 29.4 ± 1.8 J.Lm respectively. The L2 moults again to 
become L3 or infective stage by the 9th to 1Oth day of entry following mosquito bite. 
L3 has a mean length of 1503 ± 40.6J.Lm and a maximum width of 30.5 ± 0. 7 J.lm at 
day 10.5. L3 at maturity, migrates mainly to the proboscis but can be seen also in 
another parts of the insect body. It is responsible for the propogation of disease and 
may take several months to a year to become an adult worm. When an infective 
mosquito bites a susceptible host, L3 actively migrate into the wound and travel to the 
different lymphatics and subcapsular sinus. In the final host, L3 moults again to the 
fourth stage (L4) by 9 to 10 days post-entry . In experimentally infected leaf monkey 
Preshytis melalophos at two weeks post infections, B. malayi female larvae U have a 
mean length of 4710 ± 214.3 J.Lm and a maximum width of38.6 ± 2.7 J.Lm. The male 
U larvae measures 4236 ± 120.8 J.lm and 37.4 ± 1.9 J.Lm respectively (Mak, 1983).The 
final development of U to adult worms occurs approximately 35 - 40 days after initial 
infection (Edeson & Buckley, 1959). B. malayi juvenile adult worms in P. melalophos 
have an average lengths of 13.7 ± 0.3 mm and 12.6 ± 0.5 mm in females and males 
respectively (Mak, 1983). Sexual maturity occurs two to three months after infection in 
..• 
B. malayi. Variability in mean prepatent period are noted in both B. malayi and W. 
bancrofti species of filarial parasite in different hosts. For instance, the prepatent peiod 
for B. matayi in P. melatophos-is about 67 days, whereas in cats and jirds it is 80 days 
(Edeson & Wharton, 1957; Ash & Riley, 1970). The prepatent period for W. bancrofti 
in monkeys is about 8 - 18 months (Cross et at., 1979). W. bancrofti demonstrated a 
longer prepatent period in man (11 months) (Colwell et at., 1970) than B. matayi which 
4 
is about 3.5 months (Edeson & Wharton, 1957). However, variation in mean prepatent 
period were observed in both B. malayi and W bancrofti. 
-.. 
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Fig. 1.1 Life cycle of the filarial parasite 
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1.2.2. Clinical manifestation of lymphatic filariasis infection. 
The general sequence of events following filarial infection are: as prepatent 
period, asymptomatic microfilaremia, acute and finally chronic clinical filariasis. 
Lymphatic filariasis causes various acute, occult and chronic manifestations. The acute 
manifestation involves episodic attacks of adenolymphangitis associated with fever and 
malaise. The attack may last a week or more and incapacitate the patient for several 
days. It would appear that acute attacks are a significant cause of morbidity and loss of 
workdays. The most prevalent chronic manifestation of lymphatic filariasis are 
hydroceles and lymphoedema of the extremites, including its most advanced and feared 
state, elephantiasis. Milky urine, which is painless but could result in weight loss is 
also noted Chyluria occurs when lymph flow is obstructed in the thoracic duct, above 
the lymphatic branches of the kidney. The sedi.ment may contain micro filariae and red 
blood cells. Lymphoedema and elephantiasis more commonly observed in brugian 
filariasis than in cases of bancroftian filariasis. In brugian filariasis leg, arm, scrotum, 
vulva and breast are effected. In the contrast to the brugian type, bancroftian 
elephantiasis occurs beyond the knee or elbow, affecting the whole leg or arm.- Occult 
filariasis is another clinical manifestation of lymphatic filariasis infection which occurs 
when microfilaria are P!~duced and destroyed by the host immune response (Lie, 1962). 
The destruction of the microfilaria is thought to be responsible for the clinical 
syndrome. The clinical features include lymph node enlargement, usually affecting a 
.... ,~· 
single group of glands or generalised lymphadenopathy. These glands are painless, 
fimi, movable and may reach a diameter of 5 em. Tropical pulmonary eosinophilic 
(TPE) is also a form of occult filariasis and is believed to be due to a hyperimmune 
response to filarial parasite mainly microfilariae. 
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1.3 Chemotherapy of antifilarial drugs. 
1.3.1 Introduction 
In situations where vector control is relatively complex and unaffordable the 
first approach to control lymphatic filariasis is by use of antifilarial drugs that kill the 
infecting parasites such as Wbancrofti and B. malayi in human host. The currently 
available drugs are primarily microfilaricidal, with still poorly defined degrees of 
macrofilaricidal activity. However, the pursuit of filariasis control using only 
microfilaricidal drugs is still appropriate for at least two reasons: first, because the 
clearance of microfilariae from the blood can be expected to have a positive effect 
toward reducing transmission of the infection; and the other reason is that decreasing 
microfilaremia in a community yields a positive "clinical effect" on infected subjects 
(i.e.; decreasing incidence of clinical lymphoedema and adenolymphangitis attacks). 
The choice of various drugs and regimens for filariasis control must certainly depend on 
the relative effectiveness of the regimens, adverse reaction induced, as well as the 
relative cost for controlling programmes and also widely used upon. Drugs currently 
available and widely used for the treatment of lymphatic filariasis are ivermectin and 
diethylcarbamazine (DEC). The structure of these compounds are shown in Fig. 1.2. 
These two drugs are described mainly in this chapter since they are widely used in the 
-.. 
treatment of lymphatic filariasis in human. The usage of other antifilarial drugs such 
as mebendazole (MBZ), flubendazole (FBZ) and suramin for the treatment of lymphatic 
filariasis will be desc~bed briefly since their efficacy studies in human and animal 
models are limited (Fig. 1.2). 
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1.3.2. DEC and Ivermectin 
Currently five drug regimens are available for the control of lymphatic filariasis. 
The administration of"WHO-recommended standard course" of DEC 6mg/kg per day x 
12 days for W.bancrofti and x 6 days for B. malayi were found to be effective in 
treating lymphatic filarial infections (Ottesen, 1985). However, such regimes are 
expensive, require patients compliance and causes possible adverse reactions (usually, 
fever, local inflammatory reactions, gastrointestinal symptoms) (Ottesen, 1987) making 
them impractical for most control programmes. 
The administration of single dose (spaced dose ) of DEC given at weekly, 
monthly, 6 monthly, or yearly intervals has been advanced for many years by a number 
of public health workers in W. bancrofti endemic areas. (Laigret et a/., 1980). A more 
frequent yearly single dose of DEC (about 6 mglkg) regimens are found to be effective 
in decreasing microfilarial prevalence and density in both B. malayi and W. bancrofti 
infected-communities; Tahiti (Laigret eta/:, -1980);·-- --India-tpanicker eta/., 1991); 
Samoa (Kimura eta/., 1985) andFrench polynesia (Cartel et a/., 1992). 
The chemical stability of DEC permits its use as a DEC fortified salt in both 
... 
cooking and other flavouring. The effectiveness of DEC-fortified salt in decreasing the 
microfilarial prevalence of both bancroftian and brugian filariasis in large population in 
China, Taiwan and India are wel1 reviewed by Gelband (1994). Similar observation 
was made in an individual patient in whom prevalence of W. bancrofti microfilaraemia 
decreased by 97.8% after 4 months of using DEC- salt and whose corresponding 
microfilarial ( mf) density fell even more dramatically greater than 99% (J ingyuan, 
1992). However, the effectiveness of this strategy primarily determined by the 
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exclusive availability of salt fortified with DEC as well as its consumption ts 
determined by choice within the households. 
Ivermectin, a new antifilarial drug has been long employed effectively for 
control of onchocerciasis (Aziz et at., 1982; Upp et at., 1986; Albiez et at., 1988). 
Recently its effectiveness against microfilariae of both W. bancrofti and B. malayi has 
been evaluated in individual patients for a period of 12 - 24 months following drug 
administration (Richards eta!., 1991; Addis eta!., 1993; Kazura eta!., 1993; Eberhard 
et al., 1992). It is well recognised that a single dose of ivermectin 400 uglkg yields 
superior microfilaricidal activity (Richards et al., 1974). At this dose level there were 
36- 70% and 86- 99% decrease of mf prevalence and mf densities respectively after 
12 months post-treatment. 
The combination of single dose of DEC together with ivermectin seems to 
offer a more effective drug regimen than either single dose DEC or single dose 
ivermectin. The results of using-this--regimerr-mainly-comes-from individual patients 
with W. bancrofti infections receiving.this ivermectin!DEC-combination (Richards-et 
a!., 1991 ; Addison eta!., 1993 ). Studies comprising a total of 33 patients demonstrated 
a decrease in mf prevalence of 45 - 70% and mf density of 96 - 99% after 12 and 24 
..• 
months of post-treatment. In this study the dose of ivermectin used in the 
ivermectin!DEC combination was only 20 Jlg/kg (along with 6 mglkg DEC). In 
-addition safety trials have already been successfully carried out to demonstrate the 
feasibility of using ivermectin/DEC combination (Navaratnam et al., 1992; Glaziou et 
at., 1994) 
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f' 1.3.3 Suramin 
' 
Suramin is a potent filaricide used for the treatment of onchocerciasis 
(Hawking, 1978). However, its toxicity and the need for intravenous dosing under 
medical supervision for up to six weeks greatly limit its use, (Katzung, 1985). The 
antifilarial properties of suramin against human lymphatic parasite have not been 
extensively studied, since, DEC and ivermectin were the better choice of drugs in the 
treatment of brugian and bancroftian filariasis. However, investigators have reported 
the filaricidal activity of suramin against lymphatic parasite in experimentally infected 
animal models. Denham and co-workers in their study demonstrated the adultcidal 
activity of suramin against B. pahangi in cats at five weeks post-treatment (Denham & 
Me Greevy, 1977). On the other hand tertiary screening of potential filaricides, in 
Brugia malayi - Presbytis cristata animal model has identified suramin to possess 
adultcidal activity (Mak eta/., 1990). Intravenous suramin at 10 mglkg daily x 5 days 
or 17mg/k:g weekly x 5 weeks substantially reduced the recovery of live adult worms to 
50.6% and 13.6% of control respectively. ~ But no microfilaricidal activity was 
accounted. However, the suramin as~ antifilariaLagent for lymphatic filariasis obviously 
depends on envisaged preclinical and clinical evaluation, while DEC and ivermectin 
still remain as the drugs of choice . 
. .. 
1.3.4 Benzimidazole carbamate 
...,.. 
MBZ and FBZ .. derivatives of benzimidazole carbamate are widely used in the 
treatment of onchocerciasis (Domiquez-vazques et al., 1993; Rivas-Alcala et al., 1981 
a, b). In the treatment of 0. volvulus infections patients receiving 1 gm of MBZ twice 
daily for 28 days had a 50% decrease in their skin microfilariae counts for over 6 
months (Domiquez-Vazques eta/., 1983). However, poor oral absorption of MBZ as 
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well as prolonged dosing regimen do not seem to be a suitable regimen for routine 
practice. On the other hand, intramuscular (i.m.) injection ofFBZ 750 mg/week for 5 
weeks demonstrated a profound reduction of skin microfilariae in patients compared to 
patients receiving DEC 200 mg/day for 2 weeks (Rivas-Alcala et a!.. 1981 ). However, 
ulceration at the site of injections currently limit the usage of FBZ in the treatment of 
onchocerciasis. Both MBZ and FBZ are known well for their limited solubility and 
poor absorption from the gastrointestinal (GI) tract (Brugmans et al., 1971 ~ Michiels et 
al., 1982), thus making them suitable for intestinal helminth treatment (Keystone & 
Murdoch, 1979; Van den Bossche eta!., 1982). 
The filaricidal activity of MBZ and FBZ against lymphatic parasite have been 
demonstrated both in animal and humans. Denham eta!. (1978) showed the adultcidal 
activity ofMBZ against B. pahangi in experimentally infected jirds and cats. A similar 
observation was also noted following filaricidal screening of FBZ in B. pahangi 
infectedjirds and cats (Denham eta!., 1979). However, no microfilaricidal activity was 
observed in FBZ studies above.In clinical trials, the macrofilaricidal action ofMBZ was 
reported in few patients suffering from B. malayi and W bancrofti infection. These 
patients were treated with large doses of mebendazole 500 mg three times daily for 21 
days (WHO 1984). Ho~~ver, this high doses are not recommended because its 
absorptions is erratic, it is teratogenic in some animals and it can be toxic in large 
doses. A successful therapy for systemic infections disease such as lymphatic filariasis 
-
requires a sufficient quantity of drug to be absorbed to achieve a therapeutic plasma 
concentration. In view of this poorly soluble drugs such as MBZ and FBZ do not seem 
to offer a viable alternative to current drugs (DEC, ivermectin) in the treatment of this 
disease. In accordance with this new benzimidazole carbamate derivatives with better 
solubility need to be synthesized. In this thesis the bioavailability of two new 
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benzimidazole carbamate derivatives UMF-078 and UMF-058 have been investigated in 
suitable animal models. 
1.4 Mode of Action for antifilarial drugs 
1.4.1 Introduction 
Generally, extensive studies on the mode of action of parasite drugs were done 
mainly on anthelmintic agents especially benzimidazole carbamates, which have shown 
themselves to be highly effective and safe for the treatment of the majority of intestinal 
helminth infections both in human and veterinary medicine (Van Den Bossche et al., 
1982). Knowledge of the mechanism by which anti filarial drugs are absorbed and their 
mechanism of action on filarial parasites are vital in the discovery of new drugs and 
development of more effective delivery system. However, present studies are mainly 
focused on large nematodes such as Ascaris sp (Thompson et al., 1993). This probably 
might be due to its wide distribution, its importance in both human and veterinary 
medicine as well as the fact that it is large enough to study using a variety of techniques. 
Little is known on the mechanism of action of antifilarial drugs on lymphatic 
parasites such as B. malayi and W. bancrofti. The studies on the antifilarial mechanism 
mode of action of drugs such as DEC, ivermectin, suramin and benzimidazole 
carbamate on filarial parasite is still in the early stages. This probably is due in part to 
-
the lack of knowledge regarding these organisms as well as lack of suitable animal 
model for the study of these parasites in the laboratory. Indeed parasites material are 
also scarce thus limiting the scope of physiological and biochemical studies on these 
worms which may reveal promising targets for research. However, the antifilarial 
mechanism of these drugs will be discussed briefly herein. 
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1.4.2 Benzimidazole carbamate 
The mode of action of benzimidazole carbamates are usually assayed in terms of 
its antitubulin activity against microtubulin polymerization in parasite (Lacey, 1990). 
Tubulin is the functional subunit of microtubules which participate in several important 
cell functions e.g. the transport of materials within cells. Microtubules exist in dynamic 
equilibrium with tubulin and are being controlled by a range of endogenous regulatory 
proteins and co-factors. The equilibirum can be interrupted both in vivo and in vitro by 
exogenous substances known as microtubule inhibitors. Most of the inhibitors exert 
their action by binding to tubulin to prevent the self-association of sub-units onto the 
growing microtubules. This results in "capping" of the microtubule at the associating 
end with a net loss of microtubule length. The disintegration of the microtubule led to 
impaired cell functions such as mitosis, secretion and regulation of cell form. 
Both MBZ and FBZ induced the disappearance of the cytoplasmic microtubules of 
the tegumental or intestinal cells of cestodes and nematodes, which results in blocking 
the transport of secretary vessicles(Van Den Bossche, 1976; Van Den Bossche, 1986). 
This subsequently lead to impaired coating of the membranes thus decreasing the 
digestion and absorptio~ .• of nutrients. This probably might be the basis of MBZ 
induced impairment of glucose absorption in nematodes and cestodes both in vivo and 
in vitro studies (Van Den Bossche, 1976; Van Den Bossche 1986). The antitubulin 
activity was also demonstrated by other congeners ofMBZ such as albendazole (ABZ), 
parbendazole, oxibendazole and fenbendazole (Van Den Bossche eta/., 1982). Further 
evidence of tubulin dependent benzimidazole action was obtained in charcoal binding 
stability study. Colchicine, a microtubule inhibitor forms a tight pseudoirreversible 
complex with tubulin that enables the colchicine - tubulin complex to survive 
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extraction with charcoal. In addition, studies with benzimidazole resistant isolates 
parasites demonstrated a reduced charcoal-stable [H3] mebendazole binding (Lacey, 
1988). This observation further supported tubulin as the site of action of benzimidazole 
carbamate. It is also important to note that other postulated mode of action was also 
been proposed. McCracken & Stillwell ( 1991) showed that benzimidazole anthelmintic 
activity in part may be due to bioenergectic disruptions of natural membrane system 
resulting from transmembrane proton discharge. However, it is not yet possible to 
determine whether the action of these group of drugs on microtubules or on energy 
producing systems represents their primary mode of action. Further study is necessary 
to determine the exact mode of action of these chemotherapeutic agents. 
1.4.3 Diethylcarbamazine (DEC) 
DEC is the oldest and the most effective antifilarial drug used in the treatment 
of lymphatic filariasis. However, the exact mechanism of action is still unknown. 
Fujimak eta/. (1988) proposed that DEC inhibited the development of Brugia pahangi 
larvae cultured in vitro in the presence of feeder cells (LLC-M cells). It was discovered 
recently by Fujimaki and co-workers that DEC also inhibits proliferation of LLC-MK2 
cells, disrupts the cytop~~mic microtubules complex, inhibits the assembly of 
rnicrotubules in vitro and induces the disassembly of the performed microtubules in 
vitro (Fujimaki et a/., 1990). They suggested that the inhibition of larvae development 
by DEC probably might be due to the antitubulin effect of DEC on feeder cells and 
finally these cells lose their supporting function for filarial larvae. 
Subsequent study by Fujimaki et al. (1990b) also showed that B. pahangi 
larvae exposed to DEC in vitro were retarded in their development in jirds. These 
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result indicate that DEC has a direct action against the infective larvae of B. pahangi. 
The other postulated mode of action was that DEC might enhance the host parasite 
defence system by increasing the adherence of leukocytes to microfilariae mediated by 
antibodies reacting with the surface of the worms (Willy et a!., 1979). Other 
investigators suggested that DEC might affect the neuromuscular system and surface 
layers of the larvae (Hawking, 1979). Further studies need to be done since knowledge 
regarding the physiological and biochemical aspects of the neuromuscular system are 
insufficient. 
1.4.4. Suramin 
The antifilarial action of suramin upon B. pahangi has been investigated in vivo 
and in vitro (Howells eta/., 1983). With regard to its polyanioninature, suramin was 
found to be bound to the surface of worms in vitro. Subsequent in vivo studies with 
jirds fail to demonstrate the ability of suramin to alter the rates of glucose utilization, 
uptake rates of glucose, leucine and adenosine. However, ultrastructural changes were 
noted in the intestinal epithelium of worms from suramin treated jirds study, thus 
suggesting the intestinal epithelium itself might be the site of action of the drug. 
Further studies are needed to investigate suramins effect on filarial gut system since the 
..• 
knowledge regarding the pysiological aspects of the gut of filarial worm are still 
lacking. 
-
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1.4.5 Ivermectin 
The exact mechanism of action of ivermectin remains unknown but is thought to 
involve the activation of y-aminobutyric acid (GABA) pathways in the parasite via an 
effect on the GABA receptor-chloride ion channel complex (Vande Wan, 1991). 
Ivermectin potentiates the release and binding of GABA at postsynaptic sites on the 
neuromuscular junction thus paralysing the nematode worms (Gutaffson et a!., 1987). 
However, ivermectin is not filaricidal at 100-200 ug!k:g dose level as recurrence of 
microfilaraemia was encountered in polynesians infected with W bancrofti following 
ivermectin efficacy study (Cartel et a!., 1993). In addition, recent study in Brazil 
showed that high dose of ivermectin ( 400 ug!k:g) has no observable macrofilaricidal 
effect on adult W. bancrofti, although it is know to be a potent microfilaricidal agent 
(Dreyer eta!., 1995). 
. .. 
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Fig 1.2: Structural formula of antifilarial drugs. 
18 
1.5 The Pharmacokinetic and Metabolism Of Antiftlarial Drugs 
1.5.1 Introduction 
The primary objective of pharmacokinetic and drug metabolism studies in 
development of new drugs is to understand how the drug molecule is handled by the 
living animal, which involves the absorption, distribution, metabolism and excretion of 
the drug in the living system. Before reaching the stage of clinical evaluation the new 
compound, potentially a new drug is usually evaluated in numerous animal models in 
order to determine its pharmacological potency, toxicological potential and metabolic 
fate. Frequently, several animal species are used in the evaluation. Metabolism studies 
conducted in living animals provide the ultimate information regarding the 
pharmacokinetic properties and metabolic pathway of the drug molecule which can be 
used to correlate or interpret efficacy and toxicity data collected in the same species. 
Work in this thesis describe the pharmacokinetic and metabolism of new 
benzimidazole carbamate derivatives UW'-078 and UW'-058. In view of this it is 
essential to review the pharmacokinetic and metabolism of benzimidazole carbamate 
related drugs for our reference to the current status of this compound in this aspect In 
addition the metabolic fate of other important antifilarial drugs such as DEC, 
... 
ivermectin and suramin will also be discussed briefly herein. Clinical results were 
presented wherever essentiaL However, when human studies are not available, results 
of animal experiment from literature were used to described the pharmacokinetic and 
metabolism of the drugs. 
Benzimidazole carbamates are important broad-spectrum drugs primarily employed in 
the treatment of infections of helminth parasite. In human clinical practice only three 
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benzimidazole compounds; MBZ, FBZ and ABZ are currently used. However, their 
poor solubility in gastrointestinal tract limited their usage in the treatment of systemic 
disease such as lymphatic filariasis. Nevertheless, the antifilarial activity of MBZ 
(WHO 1984) as well as FBZ (Denham eta/. 1979) in limited animal and human studies 
have been demonstrated. This section will discuss some of the pharmacokinetic and 
metabolism aspect ofMBZ, FBZ and ABZ. 
1.5.2 Mebendazole 
MBZ is poorly absorbed after oral administration due to its poor aqueous 
solubility. Following administration of MBZ tablets (1.5 gm) to three fasting 
volunteers, plasma levels of MBZ remained below 17 nmol/L in two volunteers and a 
peak concentration of 17 nmol/L was noted in the third subject. When the same dose 
regimen was employed with a fatty meal, plasma concentration mounted up to 91,112 
and 142 nmol!L within 2 to 4 hr in the three treated subjects (Munst eta/., 1980). The 
increase in the absorption was probably due to the ability of the fatty meal to aid 
dissolution, through solution of the drug in the fatty media, from which it is partitioned 
into the aqueous GI contents. Dawson et a/. ( 1985) in their attempt to determine the 
absolute bioavailability of MBZ utilised a solution of radio labelled MBZ in dimethyl-
..• 
sulphoxide (DMSO) (0.25%) for oral and intravenous studies in volunteers. Following 
intravenous administration of tracer dose radio labelled MBZ ( 1.18 ug), the average 
distribution half life, elimination half-life (T 112) and rate of clearance (Cl) were 0.2 hr, 
1.12 hr and 1.163 llmin respectively. After oral administration of the similar solution 
the mean T112, Cl and time to achieve the maximum concentration (Tmax) were 0.93 h, 
0.846 1/min and 0.42 hr respectively. The bioavailability of MBZ was about 22%. 
Comparisons of area under the curve (AUC) data for two MBZ metabolites after 
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administration of the parent drug by each route indicate that absorption of MBZ from 
the GI tract at this dose is almost complete. The low bioavailability observed following 
oral administration at this subtherapeutic dose level is due to high first pass elimination. 
However, at higher dosages the poor bioavailability ofMBZ is due to a combination of 
high first pass metabolism and very low solubility of the drug. (Dawson eta/., 1985) 
In patients with hydatid disease, oral administration of MBZ 10 mglkg yield a 
plasma concentration time curves which differed considerably among subjects. The 
T112, Cmax and Tma.x ranged from 2.8 to 9.0 hr, 17.5 to 500 ug!L and 1.5 to 7.3 hr 
respectively (Witassek et. a!., 1981). Greater values of half lives were encountered 
following oral administration of large doses of MBZ compared to intravenous admin-
istration of MBZ. This difference is probably due to the absorption rate limitation of 
MBZ from GI tract This is further evident, when the T 112 (0.92 hr) value of MBZ 
following a subtherapeutic oral administration of MBZ solution compares favourably 
with the T112 (L 12 hr) value of MBZ after an intravenous treatment as described 
previously in this section (Dawson eta!., 1985). 
The metabolic tr~Q-Sformation of MBZ in vitro and in vivo has been reported 
in literature. The in vitro metabolic pattern ofMBZ in rat, dog and pig liver has been 
described by Meuldermans et a!. (1976) (Fig. 1.3). In all the three species studied 
hydroxy metabolite (methyl [5-(a-hydroxy-a phenylmethyl)-H benzimidazole-2-yl) 
carbamate was the major biotransformation product resulting from reduction of the 
ketone of the drug molecule. The major hydroxy metabolite of MBZ was also formed 
by the three different subcellular fractions (10,500 g supernatant, 100,500g supernatant, 
and microsomal enzyme) of rat, dog and pig liver. The relative activity of both soluble 
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and cellular microsomal enzyme differed for the three species. A much greater part of 
MBZ was reduced by the dog enzyme preparations than by the rats or pigs. A species 
differences was encountered for a minor amine metabolite of MBZ in the 10,000 g 
supernatant fraction and the microsomal fraction of pig liver. This metabolite (2-
amino-1-H benzimidazole-5yl) phenylmethane was produced from carbamate 
hydrolysis and was not noted in the incubates with the rat or dog liver enzyme 
preparations. The carbamate hydrolysis of MBZ was inhibited significantly by SKF-
525A indicating the involvement of the microsomal mixed function oxidation enzyme 
system. Conversely the formation of hydroxy metabolite of MBZ was only slightly 
influenced in the presence of SKF-525A inhibitor. From the overall study they 
conclude the ketone reduction ofMBZ was to be the most important in vitro metabolic 
pathway ofMBZ in dog, rat and pig liver preparations (Meuldermans eta/., 1976). 
Allan eta/. (1982) successfully identified three biliary metabolites ofMBZ in 
the rats after intravenous administration of a mixture of MBZ and 
pentadeuteromebendazole. These metabolites are methyl-5(6)-(a-hydroxybenzyl)-2 -
benzimidazole carbamate, 2-amino-5(6)-a-hydroxybenzyl benzimidazole and 2-amino 
5(6)-benzoylbenzimidazole which were obtained after enzymic conjugate hydrolysis . 
. .. 
They conclude that the major route of metabolism for MBZ was carbonyl or ketone 
reduction followed by conjugation to form glucoronides and sulphates. Conjugation 
~ 
appeared to be extensive since only unmetabolized MBZ could be detected in bile 
extracts taken before enzyme hydrolysis. Subsequent intravenous metabolic study in 
rats using eH]-MBZ and [ 14C]- MBZ further ascertain the ketone reduction ofMBZ to 
be the more important metabolic route in MBZ biotransformation (Allan et al., 1983). 
The carbamate hydrolysis remain as a trivial pathway in MBZ metabolism in rats. The 
22 
major hydroxy MBZ accounted for about 77% of the the total recovered and 99% of it 
was the conjugate metabolite (Allan et al., 1983 ). 
1.5.3. Albendazole 
There is little data available on the pharmacokinetics of ABZ in man because it 
1s largely undetectable in human plasma due to its low GI absorption and rapid 
metabolism (Penicaut eta/., 1983; Marriner eta/., 1986). When ABZ is taken orally 
either as tablets or a 2% suspension ( 400 rng) the plasma concentration of active 
metabolite ABZ sulfoxide peaked in the range of 0.22 to 0.25 mg/L at 2.0 to 3.0 hours 
post dose. The elimination T 112 ofthis metabolite was 8.5 hours (Penicaut et al., 1983). 
Marriner et a/. (1986) reported an inconsistent increase in ABZ sulphoxide 
concentration when ABZ was administered with oil and milk. Lange et a/. ( 1988) in 
their study demonstrated a significant increase of ABZ sulphoxide concentration in 
patients with echinococcosis when ABZ was given with a fatty breakfast (42.5% 
relative to fasting patients). 
ABZ undergoes extensive metabolism. The metabolic pathway noted in man 
(Penicaut eta/., 1983), cattle, sheep, rats and mice (Gyurik eta/., 1981) was similar; the 
..• 
hydrolysis of the carbamate moiety and oxidation of the sulphur atom, alkyl side chain 
and aromatic ring (Fig. 1.4). Sulphoxide and sulphone are the major metabolites of 
_. 
ABZ biotransformation in the Urine and plasma of all species and the proportion varies 
considerably among species (Delatour eta/., 1991; Lanusse eta/., 1992). However, the 
parent compound was detected in minor amount in the urine in all species (Gyurik et 
al., 1981). Microsomal incubation studies of ABZ demonstrated the formation of 
sulfoxide metabolite. The formation was mediated by cytochrome P-450 and/or FAD 
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containing monooxygenase depending on the system used; rat (Fargetton et a/., 1986), 
sheep (Galtier et al .. 1986), pig (Souhaili-El Amri et a/., 1987) or human (Rolin et a!., 
1989) liver microsomes. Unlike ABZ sulfoxidation, the oxidation to ABZ sulfone has 
been exclusively related to cytochrome P-450 in perfused rat liver preparation. ABZ is 
also known to induce its own metabolism (Souhail-El Amri et al., 1988) . 
. .. 
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